The global market for neurostimulation devices targeting chronic pain was estimated at $2.52 billion in 2018, comprised almost exclusively of spinal cord stimulation (SCS) systems. Peripheral nerve stimulation (PNS) represent a much newer development that has only emerged as a meaningful segment with the introduction of next-generation products featuring miniature neurostimulators that communicate with external power sources via wireless technology. Global sales of these next generation PNS systems were estimated at only $13.3 million in 2018 but are expected to see 34.7% real annual sales growth through 2024 to nearly $80 million as device sales increase from 2,000 in 2018 to 11,675 in 2024. A detailed analysis of the global neurostimulation devices market and the competitive landscape is included in this new report.
Abbott/St. Jude Medical
Bioness
BlueWind
Boston Scientific
Medtronic
Mainstay
Nalu Medical
Nevro
Nuvectra
Saluda Medical
SPR Therapeutics
Stimwave
Other Emerging Players
Trusted By The Companies Pioneering What’s Next
Market Intelligence
Schedule an exploratory call
Request Info17011 Beach Blvd, Suite 500 Huntington Beach, CA 92647
714-847-3540© 2024 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy